Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELESCOPE phase II study of tislelizumab + bevacizumab + nab-paclitaxel in second-line advanced driver-negative non-squamous NSCLC after acquired resistance to first-line PD-1/L1 inhibitor plus platinum doublet
ChiCTR2500099531Phase 2Not yet recruiting
- Sponsor
- Guangzhou Panyu District Central Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, bevacizumab and paclitaxel in Non-small cell lung cancer (NS-NSCLC), sponsored by Guangzhou Panyu District Central Hospital. Primary endpoint: Objective response rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
tislelizumabbevacizumabpaclitaxel
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2500099531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099531.